| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/29/2013 | US8361968 Metastin derivatives and use thereof |
| 01/29/2013 | US8361499 Controlled release hydrocodone formulations |
| 01/29/2013 | CA2694410C Pyridinoylpiperidines as 5-ht1f agonists |
| 01/29/2013 | CA2583918C Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 01/29/2013 | CA2460000C Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 01/29/2013 | CA2448665C Sustained-release analgesic compounds |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2343929C Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 01/24/2013 | WO2013012811A2 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | WO2013012269A2 Method for producing oligodendrocyte precursor cell from pluripotent stem cell |
| 01/24/2013 | WO2013011461A1 Process for the preparation of asenapine maleate |
| 01/24/2013 | WO2013011021A1 Use of c-fms antagonists |
| 01/24/2013 | WO2013010916A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | WO2013010904A1 Novel substituted indole derivatives as gamma secretase modulators |
| 01/24/2013 | WO2013010679A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | WO2013010453A1 Chemoking receptor antagonists |
| 01/24/2013 | WO2013010380A1 Btk inhibitors |
| 01/24/2013 | WO2013010274A1 Methods for diagnosing and treating alzheimer's disease by administering an ανίίangiogenic agent |
| 01/24/2013 | WO2013010218A1 Inhibition of clathrin |
| 01/24/2013 | WO2012159092A3 Medical food for cognitive decline |
| 01/24/2013 | WO2012154956A3 Anxiolytic effect of pterostilbene |
| 01/24/2013 | WO2012120356A3 Process for the preparation of (s)-(+)-or (r)-(-)-10 hydroxy dihydrodibenz[b,f]azepines by enantioselective reduction of 10, 11-dihydro-10-oxo-5h-dibenz[b,f]azepines and polymorphs thereof |
| 01/24/2013 | WO2012099952A3 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| 01/24/2013 | US20130024953 Methods of Treating Disorders Associated with Protein Aggregation |
| 01/24/2013 | US20130023584 Theaflavin Compositions, Related Processes and Methods of Use |
| 01/24/2013 | US20130023583 Theaflavin Compositions, Related Processes and Methods of Use |
| 01/24/2013 | US20130023569 Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders |
| 01/24/2013 | US20130023566 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives |
| 01/24/2013 | US20130023562 Novel piperidine derivatives |
| 01/24/2013 | US20130023556 Autotaxin inhibitors |
| 01/24/2013 | US20130023554 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof |
| 01/24/2013 | US20130023553 Pegylated opioids with low potential for abuse and side effects |
| 01/24/2013 | US20130023538 Heteroaryl Derivatives as CFTR Modulators |
| 01/24/2013 | US20130023530 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| 01/24/2013 | US20130023528 Prolylhydroxylase inhibitors and methods of use |
| 01/24/2013 | US20130023526 Isoxazolines as Therapeutic Agents |
| 01/24/2013 | US20130023524 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it |
| 01/24/2013 | US20130023521 Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| 01/24/2013 | US20130023513 Methods and Compositions for Treating Cardiovascular Disorders |
| 01/24/2013 | US20130023510 Arachidonic acid analogs and methods for analgesic treatment using same |
| 01/24/2013 | US20130023504 Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways |
| 01/24/2013 | US20130023503 Nk1 antagonists |
| 01/24/2013 | US20130023502 Substituted pyridinyl-pyrimidines and their use as medicaments |
| 01/24/2013 | US20130023499 Certain substituted amides, method of making, and method of use thereof |
| 01/24/2013 | US20130023495 Uses of dgat1 inhibitors |
| 01/24/2013 | US20130023494 Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 01/24/2013 | US20130023489 Compositions and methods for preventing and treating diseases and environmentally induced health disorders |
| 01/24/2013 | US20130023483 Template-fixed peptidomimetics with cxcr7 modulating activity |
| 01/24/2013 | US20130023475 C-met receptor regulation by angiotensin iv (at4) receptor ligands |
| 01/24/2013 | US20130022693 Plant extracts for treating neurodegenerative diseases |
| 01/24/2013 | US20130022691 Nitric Oxide Generation, Dilution, and Topical Application Apparatus and Method |
| 01/24/2013 | US20130022689 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022688 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022679 Controlled Release and Taste Masking Oral Pharmaceutical Composition |
| 01/24/2013 | US20130022676 Pulsatile drug release |
| 01/24/2013 | US20130022675 Drug delivery system |
| 01/24/2013 | US20130022670 Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration |
| 01/24/2013 | US20130022654 Controlled release pharmaceutical compositions of tapentadol |
| 01/24/2013 | US20130022646 Controlled Release Formulations of Opioids |
| 01/24/2013 | US20130022644 Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/24/2013 | US20130022642 Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases |
| 01/24/2013 | US20130022634 New composition and methods for treatment of autoimmune and allergic diseases |
| 01/24/2013 | US20130022630 Method for treating amyloid disease |
| 01/24/2013 | US20130022622 Compounds for the treatment of autism |
| 01/24/2013 | US20130022620 Assays and methods pertaining to pre-amyloid intermediates |
| 01/24/2013 | US20130022605 Antagonists against tnfr1 and methods of use therefor |
| 01/24/2013 | US20130022585 Regeneration and repair of neural tissue using postpartum-derived cells |
| 01/24/2013 | US20130022583 Direct Conversion of Cells to Cells of Other Lineages |
| 01/24/2013 | US20130022577 Probiotic compositions useful for treatment of bipolar disorder |
| 01/24/2013 | US20130022551 DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| 01/24/2013 | US20130022544 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | US20130022540 Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| 01/24/2013 | US20130022538 Aptamer-mrna conjugates for targeted protein or peptide expression and methods for their use |
| 01/24/2013 | CA2841899A1 Btk inhibitors |
| 01/24/2013 | CA2841546A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | CA2841102A1 Novel substituted indole derivatives as gamma secretase modulators |
| 01/24/2013 | CA2841013A1 Use of c-fms antagonists |
| 01/23/2013 | EP2548880A2 Compositions for increasing telomerase activity |
| 01/23/2013 | EP2548557A1 Reserpine to treat cognitive faults of the central nervous system |
| 01/23/2013 | EP2547692A2 Peptide derivatives, preparation thereof and uses thereof as vectors |
| 01/23/2013 | EP2547686A1 Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
| 01/23/2013 | EP2547685A1 Spiro-tetracyclic ring compounds as beta - secretase modulators |
| 01/23/2013 | EP2547650A1 Agomelatine hydrobromide hydrate and preparation thereof |
| 01/23/2013 | EP2547649A1 Agomelatine hydrochloride hydrate and preparation thereof |
| 01/23/2013 | EP2547363A2 Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist |
| 01/23/2013 | CN202682392U Mustard waking device |
| 01/23/2013 | CN1606545B Pyrrolidine and piperidine derivates as nk1 antagonists |
| 01/23/2013 | CN102892879A Method and composition for inducing human pluripotent stem cells |
| 01/23/2013 | CN102892761A 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists |
| 01/23/2013 | CN102892759A Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity |
| 01/23/2013 | CN102892749A Agomelatine hydrobromide hydrate and preparation thereof |
| 01/23/2013 | CN102892418A Nicotine-containing pharmaceutical compositions |
| 01/23/2013 | CN102892417A Compounds for immunoproteasome inhibition |
| 01/23/2013 | CN102892416A Pomegranate extract having high ellagic acid content, and use of pomegranate extract |
| 01/23/2013 | CN102892413A Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
| 01/23/2013 | CN102887954A Human anti-il-23 antibodies, compositions, methods and uses |
| 01/23/2013 | CN102887953A Anti-abeta antibodies and their use |
| 01/23/2013 | CN102887924A Preparation of active components for tyrosinase inhibition from agricultural and forestry waste walnut shell and application of active components |
| 01/23/2013 | CN102887910A 7-alkoxy-[1,2,4]triazolo[3,4-b]benzothiazol-3(2H)-one derivatives used as antiepileptic medicines and preparation method thereof |
| 01/23/2013 | CN102887880A Dibenzofuran derivatives, and preparation method and application thereof |